YourLifeChoices is Australia’s most established and trusted digital publication for the 50+ audience, with a core focus on helping Australians navigate midlife and the retirement landscape. Since 2000 ...
NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase ...
NKT-3447 is under clinical development by NiKang Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate ...